Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial ... - BioSpace
PRT3789, a first-in-class SMARCA2 degrader, shows encouraging anti-tumor activity in SMARCA4-mutated NSCLC and esophageal cancer patients, with generally well-tolerated doses and no dose-limiting toxicities. The study, presented at ESMO 2024, includes 65 safety evaluable patients, with 7 showing tumor shrinkage. PRT3789 is designed to treat SMARCA4 mutation-carrying cancers, which have a poor prognosis.
Reference News
PRT3789, a first-in-class SMARCA2 degrader, shows encouraging anti-tumor activity in SMARCA4-mutated NSCLC and esophageal cancer patients, with generally well-tolerated doses and no dose-limiting toxicities. The study, presented at ESMO 2024, includes 65 safety evaluable patients, with 7 showing tumor shrinkage. PRT3789 is designed to treat SMARCA4 mutation-carrying cancers, which have a poor prognosis.
PRT3789, a first-in-class SMARCA2 degrader, shows encouraging anti-tumor activity and tolerability in SMARCA4-mutated NSCLC and esophageal cancer patients. No dose-limiting toxicities or serious adverse events reported. Dose escalation continues, with 7/26 patients showing tumor shrinkage. Conference call scheduled for September 13, 2024.